search

Active clinical trials for "Venous Thrombosis"

Results 221-230 of 679

Study of Rivaroxaban for CeREbral Venous Thrombosis

Cerebral Venous Thrombosis

SECRET examines the safety of rivaroxaban versus standard-of-care for treatment of symptomatic cerebral venous thrombosis, initiated within 14 days of diagnosis.

Completed15 enrollment criteria

Efficacy of Low Molecular Weight Heparin in Superficial Vein Thrombosis

Superficial Thrombophlebitis

The aim of the study is to establish whether treatment of superficial vein thrombosis (SVT) with low-molecular-weight heparin in preventive or therapeutic doses prevents disease progression and thromboembolic events (deep vein thrombosis and pulmonary embolism), whether efficacy of low-molecular-weight heparin differs with regard to the dosage used (prevention, treatment), and to recognize groups of patients in which treatment with heparin is most efficient, as well as to determine factors that influence the efficacy of SVT treatment with heparin.

Completed17 enrollment criteria

Evaluation of the Duration of Therapy for Thrombosis in Children

Venous Thrombosis

The Kids-DOTT trial is a randomized controlled clinical trial whose primary objective is to evaluate non-inferiority of shortened-duration (6 weeks) versus conventional-duration (3 months) anticoagulation in children with first-episode acute venous thrombosis. The first stage of the trial has consisted of a pilot/feasibility component, which then continues as the definitively-powered trial.

Completed12 enrollment criteria

Fondaparinux as Monotherapy for DVT and/or Pulmonary Embolism

Deep Vein ThrombosisPulmonary Embolism

To determine whether fondaparinux as monotherapy without warfarin is effective and safe for long-term (90 days) treatment of DVT and/or PE, thus gaining new long-term experience and data using fondaparinux.

Completed14 enrollment criteria

Randomized Controlled Trial of Anticoagulation vs. Placebo for a First Symptomatic Isolated Distal...

Distal (Calf) Deep-vein Thrombosis

CACTUS-PTS is a randomized, placebo-controlled, double-blind study which aims primarily to determine the effectiveness of a 6 week course of therapeutic-dose LMWH (nadroparine) injections vs. placebo in patients with a first symptomatic isolated distal (calf) deep-vein thrombosis (IDDVT), as measured by rate of proximal DVT and symptomatic PE at 6 weeks. Additionally, the study aims to determine if the 6 week course of treatment with therapeutic-dose LMWH (nadroparine) injections, compared to placebo, decreases the frequency of post-thrombotic syndrome (PTS) at 1 year.

Completed19 enrollment criteria

Pharmacogenetic Dosing of Warfarin

StrokeVenous Thrombosis2 more

Purpose: Warfarin is now the most commonly used oral anticoagulant. This drug has inter-individual variability due to the genetic polymorphisms in the warfarin metabolizing enzyme, CYP2C9 and warfarin target, VKORC1. The investigators' team developed a pharmacogenetic dosing algorithm which can predict patients required warfarin dose, thus could prevent warfarin induced warfarin adverse events. Methods: The investigators recruited patients with indications for warfarin, the genotypes of VKORC1 and CYP2C9 were determined by the hospitals and verified by National Center for Genome Medicine. The investigators then randomized the patients to one of three arms: 1. Warfarin dose predicted by dosing algorithm developed by the International Warfarin pharmacogenetic Consortium (IWPC), 2. Algorithm developed by the Taiwan Warfarin Consortium and 3. Standard of care. The investigators aimed to determine whether using genetic dosing algorithm can lead to more stable dose and safer use of the drug.

Completed9 enrollment criteria

EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis

Venous Thromboembolism

The purpose of this study is to find out whether rivaroxaban is safe to use in children and how long it stays in the body. Safety will be assessed by looking at the incidence and types of bleeding events. There will also be a check for worsening of blood clots.

Completed16 enrollment criteria

Placebo-controlled Study of NPB-06 in Patients With Portal Vein Thrombosis

Portal Vein Thrombosis

Patients with portal vein thrombosis, who have chronic liver diseases especially liver cirrhosis associated with low levels of AT III, will receive intravenous injection of NPB-06 or placebo. The superiority of NPB-06 to placebo as anticoagulative agent will be verified in a randomized, double-blind, parallel-assignment design based on the proportion of patients obtained complete recanalization or partial recanalization of portal vein thrombosis. The safety of NPB-06 will be evaluated based on adverse events and adverse drug reactions (ADRs) observed between administration and 21 days after administration in comparison with the placebo group.

Completed23 enrollment criteria

Osteopathic Treatment and Deep Vein Thrombosis (DVT)

Deep Vein Thrombosis (DVT)

Osteopathic treatment will provide: A significant reduction of pain and swelling of the affected DVT leg An increase in the quality of life (QOL) for individuals with DVT of the leg Improved signs and symptoms of the post thrombotic syndrome of the affected DVT leg

Completed18 enrollment criteria

Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation

Permanent Atrial FibrillationVenous Thrombosis2 more

The VICTORIA Study (Vascular CalcIfiCation and sTiffness induced by ORal antIcoAgulation) is a comparative, parallel, prospective, controlled and randomized study of the structural and functional impact of rivaroxaban versus anti-vitamin K drugs on the arterial vasculature.

Completed25 enrollment criteria
1...222324...68

Need Help? Contact our team!


We'll reach out to this number within 24 hrs